Researcher.Life Logo

Archivos de prevención de riesgos laborales : Impact Factor & More

eISSN: 1578-2549pISSN: 1138-9672
JournalOpen Access

Key Metrics

CiteScore
0.1
Recommended pre-submission checks
Powered by Paperpal by Editage

Archivos de prevención de riesgos laborales Journal Specifications

Indexed in the following public directories

  • DOAJ DOAJ
Overview
Publisher Societat Catalana de Seguretat i Medicina del Treball (SCSMT)
Language Spanish,Catalan
Publication Time20
Editorial Review ProcessDouble anonymous peer review
General Details
LanguageSpanish,Catalan
Website URLVisit website
Publication Details
Publication Time 20
Editorial Review Detail
Editorial TeamVisit website
Review ProcessDouble anonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicyDulcinea
License typeCC BY-NC-ND
OA statementVisit website
View less

Planning to publish in Archivos de prevención de riesgos laborales ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Archivos de prevención de riesgos laborales

MORPHEUS-Lung: biomarkers and clinical response to atezolizumab+bevacizumab+stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.
  • 16 Apr 2027
  • Lung cancer (Amsterdam, Netherlands)
Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy
  • 1 Jul 2026
  • Lung Cancer
Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers.
  • 1 Jun 2026
  • Lung cancer (Amsterdam, Netherlands)
New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC.
  • 1 Jun 2026
  • Lung cancer (Amsterdam, Netherlands)
Association of tumor CD73 expression with clinical outcomes in small cell lung cancer treated with first-line chemo-immunotherapy.
  • 1 Jun 2026
  • Lung cancer (Amsterdam, Netherlands)
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.
  • 1 Jun 2026
  • Lung cancer (Amsterdam, Netherlands)
MORPHEUS-Lung: biomarkers and clinical response to atezolizumab+bevacizumab+stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.
  • 16 Apr 2027
  • Lung cancer (Amsterdam, Netherlands)
Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy
  • 1 Jul 2026
  • Lung Cancer
Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers.
  • 1 Jun 2026
  • Lung cancer (Amsterdam, Netherlands)
New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC.
  • 1 Jun 2026
  • Lung cancer (Amsterdam, Netherlands)
Association of tumor CD73 expression with clinical outcomes in small cell lung cancer treated with first-line chemo-immunotherapy.
  • 1 Jun 2026
  • Lung cancer (Amsterdam, Netherlands)
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.
  • 1 Jun 2026
  • Lung cancer (Amsterdam, Netherlands)

FAQs on Archivos de prevención de riesgos laborales